A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Clinical trial NCT03110822 · RECRUITING

Trial details

NCT number: NCT03110822
Sponsor: Oncotherapeutics
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2017-02-01
Primary completion: 2024-09-01
Enrollment: 134

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.